2,3,4,6,7,8-hexahydro-1H-quinolizine | 6391-47-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹嗪类
• 英文名称: 2,3,4,6,7,8-hexahydro-1H-quinolizine
• 英文别名: 1,3,4,6,7,8-hexahydro-2H-quinolizine；1,3,4,6,7,8-hexahydro-2H-quinolizin；1,3,4,6,7,8-Hexahydro-2H-chinolizin；Δ^1,10-Hexahydrochinolizin VI；Δ^1,10-Hexahydrochinolizin；3,4,6,7,8,9-Hexahydro-2H-chinolizin；9(10)-Dehydroquinolizidine
• CAS: 6391-47-5
• 化学式: C₉H₁₅N
• 分子量: 137.225
• InChiKey: XRJWBIZYAUPOEA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,3,4,6,7,8-hexahydro-1H-quinolizine 在 高氯酸 、 硼烷四氢呋喃络合物 、 2-甲基-2-丁烯 、 碘 、 magnesium 、 zinc dibromide 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 30.0h， 生成 4-(octahydro-1H-quinolizin-9a-yl)butan-1-ol
  参考文献：
  名称：

  Clofazimine analogs with antileishmanial and antiplasmodial activity

  摘要：

  A set of novel riminophenazine derivatives has been synthesized and evaluated for in vitro activity against chloroquine-sensitive (CQ-S) and chloroquine-resistant (CQ-R) strains of Plasmodium falciparum and against different species of Leishmania promastigotes. Most of the new compounds inhibited the growth of Leishmania promastigotes as well as CQ-S and CQ-R strains of P. falciparum with IC50 in submicromolar range, resulting in the best cases 1-2 orders of magnitude more potent than the parent compound clofazimine. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.028
• 作为产物：
  描述：

  5-(2-氧代哌啶-1-基)戊酸乙酯 在 soda lime 作用下， 生成 2,3,4,6,7,8-hexahydro-1H-quinolizine
  参考文献：
  名称：

  Clofazimine analogs with antileishmanial and antiplasmodial activity

  摘要：

  A set of novel riminophenazine derivatives has been synthesized and evaluated for in vitro activity against chloroquine-sensitive (CQ-S) and chloroquine-resistant (CQ-R) strains of Plasmodium falciparum and against different species of Leishmania promastigotes. Most of the new compounds inhibited the growth of Leishmania promastigotes as well as CQ-S and CQ-R strains of P. falciparum with IC50 in submicromolar range, resulting in the best cases 1-2 orders of magnitude more potent than the parent compound clofazimine. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.11.028

文献信息

• COMPOUND AND COLOR CONVERSION FILM COMPRISING SAME
  申请人：LG CHEM, LTD.

  公开号：US20180186817A1

  公开（公告）日：2018-07-05

  The present specification relates to a novel compound, and a color conversion film, a backlight unit and a display apparatus including the same.

  本说明书涉及一种新型化合物，以及包括该化合物的颜色转换膜、背光单元和显示装置。
• Octahydro-indolizine and quinolizine and hexahydro-pyrrolizine
  申请人：——

  公开号：US20030013733A1

  公开（公告）日：2003-01-16

  The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions.

  这项发明涉及替代融合双环化合物，包含它们的药物组合物，以及使用它们治疗或预防组织胺介导的疾病和症状的方法。
• OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES
  申请人：Apodaca Richard

  公开号：US20090263322A1

  公开（公告）日：2009-10-22

  The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions.

  这项发明涉及替代的融合双环化合物，包含它们的药物组合物，以及使用它们治疗或预防组胺介导的疾病和病况的方法。
• 4-substituted octahydroquinolizine analgesic compounds and octahydroquinolizinium intermediates
  申请人：McNeilab, Inc.

  公开号：EP0241292A2

  公开（公告）日：1987-10-14

  Octahydroquinolizine and corresponding octahydroquino­lizinium compounds of formulae (I) and (Va): where A is a 3 to 7 membered carbocyclic ring, R¹ is a substituent, n is 0-2, x is 0-3, and Y is an anion. Also, pharmaceutical compositions for treating pain containing (I) and methods for synthesis and use as well as novel intermediates in the synthesis.

  八氢喹嗪和相应的式 (I) 和 (Va) 的八氢喹嗪鎓化合物： 其中 A 是 3 至 7 个成员的碳环，R¹ 是取代基，n 是 0-2，x 是 0-3，Y 是阴离子。此外，还包括含有(I)的治疗疼痛的药物组合物、合成和使用方法以及合成过程中的新型中间体。
• Substituted hexahydroarylquinolizines
  申请人：Merck & Co., Inc.

  公开号：EP0259092A1

  公开（公告）日：1988-03-09

  Certain substituted hexahydroarylquinoli­zines and pharmaceutically acceptable salts thereof are peripherally selective α₂-adrenoceptor antagonists. The compounds are adapted to be employed for the treatment of certain pathological disorders such as hypertension, diabetes, disorders involving platelet aggregation and the like without side effects attributable to effect on the central nervous system.

  某些取代的六氢芳基喹嗪类化合物及其药学上可接受的盐类是外周选择性 α₂-肾上腺素受体拮抗剂。这些化合物可用于治疗某些病理紊乱，如高血压、糖尿病、血小板聚集紊乱等，且不会对中枢神经系统产生副作用。